Results from two concurrent, prospective, double-blind, multi-center clinical trials show that pegaptanib (Macugen), an anti-vascular endothelial growth factor therapy, is an effective treatment for neovascular age-related macular degeneration (AMD).
Pfizer announced today that it has submitted a supplemental new drug application to the U.S. Food and Drug Administration seeking approval for AROMASIN in the adjuvant treatment of postmenopausal women with estrogen receptor positive or receptor unknown early-stage breast cancer.
Vesicare(r) (solifenacin succinate) has been approved by the FDA for the treatment of overactive bladder with symptoms of urgency, frequency, and urge incontinence. OAB affects an estimated 17-20 million men and women in U.S.
New data showed that AstraZeneca's CRESTOR(R) (rosuvastatin calcium) at 10 and 20 mg reduced LDL-C or "bad" cholesterol by 37 and 46 percent, compared to 32 and 39 percent at similar doses with atorvastatin in African-American patients.
Remarkable advances in assistive technology continue to offer hope for improved function and greater independence, but far too many people are not benefiting from it. The impact on their lives -- and society -- is staggering.
Teleconference to recap presentations given on TB therapies in development from the IUATLD conference in Paris and the ICAAC conference in Washington DC. Latest scientific studies and results will be shared; briefings from the TB Alliance, leading pharmaceutical companies and academic laboratories will participate.
The treatment effect with the investigational drug Macugen extends for two years in patients with neovascular or wet, age-related macular degeneration, who are at risk of losing their vision. A treatment benefit was also seen for patients who received Macugen for two years compared to those only receiving one year of therapy.
Together Rx LLC has appointed Roba Whiteley as its new executive director. Together Rx, the nation's most widely enrolled private prescription savings program, has over 1.4 million cardholders and has saved seniors more than $500 million.
Results of a multi-center, prospective study involving two leading drug-eluting stents were presented today, with data indicating that patients with long areas of vessel blockage treated with the Cypher Sirolimus-eluting Stent had less in-stent late loss and less in-stent restenosis.
The first, integrated data analysis from multiple clinical trials to focus exclusively on the benefits of the Sirolimus-eluting Coronary Stent in women shows that female patients who received the CYPHER® Stent are five times more likely to avoid a repeat reblockage in the treated arteries.
A new approach for assessing glaucoma risk factors could be the first step in helping ophthalmologists determine the risk of progression from ocular hypertension to glaucoma and blindness.
AstraZeneca stated that Public Citizen's Health Research Group's (HRG) petition to remove CRESTOR® (rosuvastatin calcium) from the market provides no scientific basis, is inaccurate and must be denied.
A new sequential dose-dense chemotherapy regimen including ELLENCE significantly improves survival in high-risk breast cancer patients.
Combination of CAMPTOSAR(r) and AVASTIN(tm) shows survival benefit in first-line treatment of advanced colorectal cancer. Combination of CAMPTOSAR and Erbitux(tm) found safe, well-tolerated, and active in first-line treatment.
Results from the Phase III Four Arm Cooperative Study (FACS) of first-line treatment regimens for advanced non-small cell lung cancer suggested that the combination of CAMPTOSAR(r) (irinotecan HCL for injection, CPT-11) and cisplatin should provide the best overall survival benefits and toxicity manageability
New approaches to care for the leading cause of blindness in the elderly are required as the population ages. Nearly all retina specialists are greatly alarmed by the increasing number of cases of wet age-related macular degeneration and believe the disease will have a serious impact on the public.
Serono, Inc., a leader in reproductive health, announced a series of national teleconferences to mark the launch of Fertility LifeLines(tm), a free educational service that offers customized information and support to people with fertility health concerns.
Researchers at Cornell Medical College announced today the funding of an important new cancer research study using new CT screening technology that gives doctors a more defined picture of potential cancer development.
Breast cancer patients who switched to AROMASIN were more likely to remain cancer free, a new study shows. Results from the study challenge standard tamoxifen therapy.
Prionics®-Check WESTERN is the most accurate rapid-test procedure in the world. It has been used on more than 15 million cattle samples worldwide, and there have been no false positives recorded. Prionics AG has more than 50 percent share of the world market for BSE testing procedures.
Results from a new survey show that, despite a record number of new treatment options being researched and available for multiple myeloma patients, oncologists are referring surprisingly few patients to NCI-designated cancer centers or enrolling them in leading-edge clinical trials.
Study conducted by researchers at the University of Pittsburgh examines the use of inhaled nitric oxide in newborns with hypoxemic respiratory failure compared with an invasive surgery and the use of a heart-lung machine. The study found the inhaled nitric oxide treatment resulted in a cost savings of up to $4,400.
The director of the Institute for Ethnobotany has confirmed a dietary link to a Western Pacific neurodegenerative disease, amyotrophic lateral sclerosis-Parkinsonism dementia complex (ALS-PDC). He found that a neurotoxin produced by cyanobacteria accumulates and becomes more potent as it moves through the food chain of the Chamorro people of Guam.
The FDA has approved a new pre-filled syringe for Ovidrel, making it the first liquid, ready-to-inject therapy for infertility treatment in the US that can be administered in one step.
A new study provides additional evidence of the value of aromatase inhibitors for the treatment of breast cancer. In this phase II clinical study, exemestane demonstrates a high response rate for first-line treatment of advanced breast cancer in postmenopausal women.
AstraZeneca's CRESTOR® (rosuvastatin calcium) receives FDA approval. CRESTOR significantly lowers LDL cholesterol by as much as 63%
Two clinical trials involving more than 600 patients showed that 48.1% of patients treated with quetiapine fumarate achieved a response [defined as >50% decrease from baseline YMRS (Young Mania Rating Scale) score].
New Phase III data show that AstraZeneca's investigational lipid-lowering medication CRESTOR(r) reduced LDL or "bad" cholesterol from 46 percent to 55 percent and increased HDL or "good" cholesterol by 7.6 percent to 9.6 percent at the same doses in patients with elevated cholesterol levels.
Treatment can alleviate year-round allergy symptoms caused by pet dander, dust mites, and molds.
New study is the first of its kind to examine the effects of statin therapy on patients with healthy cholesterol levels and elevated C-reactive protein levels.
NCCRA launches new campaign to educate physicians and the public on importance of colorectal cancer screening and advances in treatment.
The idea that men are from Mars and women are from Venus has received another boost, as researchers have discovered that sex differences may play a role in trying to quit smoking.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right